<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00715364</url>
  </required_header>
  <id_info>
    <org_study_id>NTx™-265-CP-201-IS (US)</org_study_id>
    <nct_id>NCT00715364</nct_id>
  </id_info>
  <brief_title>REGENESIS (US): A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients</brief_title>
  <acronym>REGENESIS</acronym>
  <official_title>A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stem Cell Therapeutics Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stem Cell Therapeutics Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety and tolerability of NTx™-265 when given to acute ischemic stroke&#xD;
      patients.&#xD;
&#xD;
      To assess the neurological outcome in acute ischemic stroke patients treated with NTx™-265,&#xD;
      when compared with patients given a placebo control.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Anticipated">September 2010</completion_date>
  <primary_completion_date type="Anticipated">June 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>screening to Day 90</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>mRS</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NIHSS</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barthel Index</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Action Research Arm Test</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gait Velocity Test</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Boston Naming Test</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Line Cancellation Test</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trails A &amp; B Test</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NTx™-265: rhCG, then rEPO</intervention_name>
    <description>rhCG 385 µg, SC, on Day 1, 3, and 5 of study participation, then&#xD;
rEPO 30,000 IU, IV, on Day 7, 8, and 9 of study participation</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Ovidrel</other_name>
    <other_name>Epogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline Placebo</intervention_name>
    <description>Saline SC, on Day 1, 3, and 5 of study participation, then&#xD;
Saline IV, on Day 7, 8, and 9 of study participation</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Sodium Chloride 0.9%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-85.&#xD;
&#xD;
          -  NIHSS score 6-24 within 24-48 hours after stroke onset and enrolment.&#xD;
&#xD;
          -  Stroke is ischemic in origin, supratentorial, and radiologically confirmed (CT scan or&#xD;
             diagnostic MRI) prior to enrolment.&#xD;
&#xD;
          -  Patient is 24-48 hours from time of stroke onset when the first dose of NTx™-265&#xD;
             therapy is administered. Time of onset is when symptoms began; for stroke that&#xD;
             occurred during sleep, time of onset is when patient was last seen or was&#xD;
             self-reported to be normal.&#xD;
&#xD;
          -  Reasonable expectation of availability to receive the full 9 day NTx™-265 course of&#xD;
             therapy, and to be available for subsequent follow-up visits.&#xD;
&#xD;
          -  Reasonable expectation that patient will receive standard post-stroke physical,&#xD;
             occupational, speech, and cognitive therapy as indicated.&#xD;
&#xD;
          -  Female patient is either:&#xD;
&#xD;
               1. not of childbearing potential, defined as postmenopausal for at least 1 year or&#xD;
                  surgically sterile (bilateral tubal ligation, bilateral oophorectomy or&#xD;
                  hysterectomy) or,&#xD;
&#xD;
               2. if of childbearing potential, agrees to use two of the following effective&#xD;
                  separate forms of contraception throughout the study, up to and including the&#xD;
                  follow up visits: i) condoms, sponge, foams, jellies, diaphragm or intrauterine&#xD;
                  device (IUD) contraceptives (e.g. implants, injectables, combined oral, etc.) OR&#xD;
                  ii) a vasectomized partner OR iii) abstinence&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients presenting with lacunar, hemorrhagic and/or brain stem stroke&#xD;
&#xD;
          -  Patients classified as comatose, defined as a patient who requires repeated&#xD;
             stimulation to attend, or is obtunded and requires strong or painful stimulation to&#xD;
             make movements (NIHSS 1A score must be &lt;2)&#xD;
&#xD;
          -  Women who have tested positive for pregnancy, or are breast-feeding, or are not using&#xD;
             a highly effective method of birth control that can be maintained for the duration of&#xD;
             the study&#xD;
&#xD;
          -  Serum hemoglobin &gt; 16 g/dL (males) or &gt; 14 g/dL (females); or platelet count &gt;&#xD;
             400,000/mm3&#xD;
&#xD;
          -  Advanced liver, kidney, cardiac, or pulmonary disease; the former will be&#xD;
             operationally defined using NCI Toxicity Criteria (Grade 2 or higher)&#xD;
&#xD;
          -  Serum bilirubin &gt; 1.5 x ULN&#xD;
&#xD;
          -  Alkaline phosphatase &gt; 2.5 x ULN&#xD;
&#xD;
          -  AST or ALT &gt; 2.5 x ULN&#xD;
&#xD;
          -  Creatinine &gt; 2.0 x ULN&#xD;
&#xD;
          -  Patients with known and documented Transferrin saturation &lt;20% or ferritin &lt; 100 ng/ml&#xD;
&#xD;
          -  Patients with known and documented elevated PSA levels&#xD;
&#xD;
          -  Patients with a known history of hypercoagulability, including known&#xD;
             cardiolipin/antiphospholipid antibody syndrome&#xD;
&#xD;
          -  Expected survival &lt; 1 year&#xD;
&#xD;
          -  Allergy or other contraindication to hCG&#xD;
&#xD;
          -  Allergy or other contraindication to epoetin alfa:&#xD;
&#xD;
          -  A known diagnosis of cancer (except non-malignant skin cancer)&#xD;
&#xD;
          -  Uncontrolled hypertension, defined in the context of acute stroke as blood pressure&#xD;
             persistently above 220 mm Hg systolic or 120 mm Hg diastolic despite antihypertensive&#xD;
             therapy&#xD;
&#xD;
          -  Use of either hCG or epoetin alfa within the previous 90 days&#xD;
&#xD;
          -  Any condition known to elevate hCG, active in the prior 24 months, e.g.,&#xD;
             choriocarcinoma or germ cell tumor&#xD;
&#xD;
          -  Patients with a pre-stroke/pre-morbid modified Rankin Score (mRS) ≥ 2&#xD;
&#xD;
          -  Any patients living in a nursing home or supervised living center. Patients must be&#xD;
             historically fully independent in all activities of daily living including banking,&#xD;
             shopping, cooking, toileting, showering and dressing&#xD;
&#xD;
          -  Any other medical condition or degree of stroke such that, in the investigator's&#xD;
             opinion, the patient should not be included in the trial&#xD;
&#xD;
          -  With the exception of the qualifying stroke, any other stroke within the previous 3&#xD;
             months&#xD;
&#xD;
          -  Patients who cannot take anti-platelet or anti-coagulant therapy&#xD;
&#xD;
          -  Pre-existing and active major psychiatric or other chronic neurological disease&#xD;
&#xD;
          -  Consume, on average, greater than 14 alcoholic drinks per week, or have a history of&#xD;
             substance abuse or dependency within 12 months prior to the study&#xD;
&#xD;
          -  Currently participating in another investigational study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven C Cramer, MD, MMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurology, University of Califonia, Irvine Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hoag Memorial Hospital Presbyterian</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92658</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868-4280</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <study_first_submitted>July 9, 2008</study_first_submitted>
  <study_first_submitted_qc>July 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2008</study_first_posted>
  <last_update_submitted>September 2, 2011</last_update_submitted>
  <last_update_submitted_qc>September 2, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

